Sciety summarises 2024 – A year of growth and innovation

NEWS. 2024 has been a successful year for Sciety. We celebrated 10 years as a company, welcomed new key members to our team and saw several of our portfolio companies achieve significant advances that strengthen their market position. Throughout the year, we have continued to bridge scientific breakthroughs with tangible societal benefits. We have funded leading companies across areas ranging from advanced self-sampling to groundbreaking pharmaceutical treatments. Together with Sciety Venture Partners, we invested in four innovative companies this year. Let’s take a closer look at this year’s most significant highlights!

Key milestones for Sciety

Investments during the year

In spring, Sciety and Sciety Venture Partners invested 16.8 million SEK in Capitainer, a Swedish medtech company that has developed a unique platform for self-sampling of blood. This investment will enable Capitainer to scale up production and strengthen its sales organisation in Europe and the USA – a crucial initiative supporting the company’s international expansion.

In autumn, Sciety and Sciety Venture Partners invested 45 million SEK in PeptiSystems, a Swedish biotech company that has developed revolutionary technology for large-scale production of peptide and oligonucleotide drugs. The capital will be used to increase production capacity and scale up sales, enabling the company to become a key market player.

Sciety and Sciety Venture Partners also participated in TIRmed Pharma‘s share issue, where the company raised 47 million SEK. TIRmed Pharma is developing the next generation of treatment for atopic dermatitis (eczema), a chronic condition affecting millions globally. The capital enables an upcoming phase Ib study to examine safety and early signs of efficacy – an important step towards improving patients’ lives worldwide.

In autumn, Evidence completed a share issue raising 6 million SEK. Evidence has developed a unique digital platform that simplifies and streamlines planning and operations management in healthcare. With over 200 public and private healthcare units as customers in Sweden and growing international presence, Evidence is well-positioned for continued growth.

We are excited to follow the companies’ development.

Strengthened team with new members

At the start of the year, we welcomed Marcus Hjort as Investment Associate. Marcus holds a medical degree and PhD from Uppsala University and joins us from Danderyds Hospital where he worked as a specialist physician in cardiology. Marcus’s medical expertise significantly enhances our investment process.

In August, Tor Sander joined as Investment Associate. Tor previously worked for Boston Consulting Group, where he provided strategic consulting in life science. Tor brings valuable expertise in pharmaceuticals, diagnostics and medtech.

During autumn, we introduced Nick Roelofs as Venture Partner. Nick has over 40 years of leadership experience in life science and has shaped the strategic direction of companies such as Agilent Technologies and Bio-Rad Laboratories. As an advisor to private equity firms including Summa Equity and Nordic Capital, he has led investments in companies such as Olink, where he played a key role in its sale to Thermo Fisher for 34 billion SEK.

Sciety celebrated 10 years

Time flies when you’re having fun – this year we celebrated 10 years as a company! When Sciety was founded in 2014, the vision was clear – to bridge scientific breakthroughs with societal benefits. Ten years later, we have grown to become one of the Nordic region’s leading investors in life science and digital health, with over one billion SEK invested in 26 innovative companies. Read more about our journey here.

 

Portfolio company progress 2024 – selected highlights

Capitainer

Medtech company Capitainer took a major step towards international growth by opening a new laboratory in Rhode Island, US early this year. This strengthens the company’s presence in the US medical testing market and marks a significant milestone in the company’s global expansion. 

In spring, Capitainer entered a strategic collaboration agreement with Life Genomics to broaden the use of their self-sampling technology, initially focusing on tests for hypothyroidism. The collaboration opens up new applications for the company’s technology.

Capitainer also launched Capitainer®SEP10, a new CE-marked and FDA-registered sampling card for blood collection and automatic plasma separation. The launch represents a technical breakthrough in self-sampling and sets a new industry standard. Additionally, the company established a subsidiary in the USA with headquarters in Providence, further strengthening their American market presence and international expansion.

Akiram Therapeutics

Biotech company Akiram Therapeutics began the year with a significant milestone, entering into a manufacturing agreement with Karolinska University Hospital for the production of its radiopharmaceutical treatment for solid tumours. The agreement secures drug manufacturing for upcoming clinical trials.

In autumn, the company received approval from the Swedish Medical Products Agency to initiate a phase 1 study with their drug candidate 177Lu-AKIR001. The treatment is a new type of molecular radiotherapy where a targeting molecule is directed with high precision against tumour cells. The approval marks the company’s first step into clinical development and important validation of the technology.

Neogap Therapeutics

Neogap Therapeutics made significant progress during the year and was granted patents in both Australia and China for its innovative method for treating and diagnosing multiple sclerosis. The patents strengthen the company’s intellectual property rights in two strategically important markets.

The company also received 5 million SEK in EU funding from Eurostars to develop a method for analysing T-cell activity against cancer. The funding validates the company’s technology and enables continued development.

Towards the end of the year, Neogap initiated a strategic production partnership with NorthX Biologics to develop scalable manufacturing of its treatment. The collaboration, supported by EIC Accelerator, ensures the company’s future production capacity for clinical trials.

PharmNovo

PharmNovo reported successful phase I results for its drug candidate PN6047, an innovative pain treatment without the negative effects and abuse risks associated with traditional opioids. The results confirm the drug’s potential and provide a foundation for continued development.

The company also secured significant funding from EIC Accelerator including a grant of 2.5 million EUR and conditional investments of up to 15 million EUR. This funding enables the next crucial step in development, phase IIa studies, further strengthening PharmNovo’s market position.

Elypta

The diagnostics company Elypta presented promising interim results from the LEVANTIS study, where their technique for analysing biomarkers in urine could predict 80% more future cancer cases compared to current methods. These results underscore the technology’s potential to revolutionise cancer screening globally.

During autumn, Elypta published a new study showing that their technology outperforms traditional risk factors in predicting bladder cancer. Elypta was also selected for the European Innovation Council’s prestigious Scaling Club. These advances strengthen the company’s position in early cancer diagnostics.

Encare

Healthtech company Encare has achieved significant success in international markets throughout the year. The company’s ERAS® Interactive Audit System was implemented at Kaiser Permanente Los Angeles Medical Center and leading hospitals in Asia, including Seoul University Hospital and Nagahama City Hospital.

In the domestic market, expansion continued with implementation at Falu Lasarett, where the company’s software is used for registration and follow-up in colorectal surgery. The continued growth in the home market confirms the value of the company’s solution.

Synartro

The biotech company Synartro published a new preclinical study showing that their injectable formulation SYN321 effectively reduces inflammation and protects cartilage. The study was conducted using advanced technology that simulates human cartilage tissue in a chip model, providing strong scientific support for the treatment’s mechanism of action.

The company was also awarded the European Commission’s Seal of Excellence for its drug candidate SYN321, awarded to project proposals deemed high-quality and attractive for investment. This represents significant external validation of the company’s development programme.

It has been a successful year with many important milestones for our portfolio companies. Now we look forward to an exciting 2025!

Receive news and invitations from Sciety

Join our newsletter to be the first to know about new investment opportunities and receive invitations to company presentations, seminars, and events.

Sign up here

Disclaimer: The information contained in our emails and communications is intended for informational purposes only and is not intended to constitute advice or recommendations on any investment. We do not guarantee the accuracy, completeness, timeliness, or suitability of any information provided. Please note that our communications are not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation. In particular, our communications are not intended for persons in the United States or Australia. We do not accept any liability for any loss or damage arising from the use of our communications, including but not limited to any investment decisions made based on the information provided. Furthermore, please note that any investment in private companies involves a high degree of risk and is not suitable for all investors. Before making any investments, you must read and accept our general terms and conditions for investments, which can be found at the following link: General Terms and Conditions for Investments.

Latest news